Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03823885 · ClinicalTrials.gov registry record · NA

ECigs, Inflammation and Oxidative Stress

A NA study of E-cigarettes, Oxidative Stress, Inflammation, sponsored by University of California, Los Angeles.

Completed
Registry status
NA
Development phase
148
Enrollment target
1
Study location

NCT03823885: Completed NA study of E-cigarettes, Oxidative Stress, Inflammation, sponsored by University of California, Los Angeles.

NCT03823885 is a NA study of E-cigarettes, Oxidative Stress, Inflammation that has completed, run by University of California, Los Angeles. The registered enrollment target is 148 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03823885, a NA study of E-cigarettes, Oxidative Stress, Inflammation, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
NA
Development phase
148 participants
Enrollment target
1
Study location

Study Summary

Randomized controlled trial of acute use of electronic cigarette effect on oxidative stress and inflammation.

Primary Outcome

cellular oxidative stress, including cytoplasmic and mitochondrial oxidative stress, in viable cells

Interventions

  • OTHER e-cigarette
  • OTHER empty (-cigarette sham control)

Study Locations (1)

California

  • UCLA - Los Angeles

Trial Details

FieldValue
Enrollment Target 148 participants
Start Date 2019-02-08
Est. Completion 2023-10-01
Phase NA

What the finished NCT03823885 record still lists

NCT03823885 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).

The record links to 1 condition, with E-cigarettes, Oxidative Stress, Inflammation appearing as the primary indexed condition, and to 2 interventions - of which e-cigarette is the first listed.

NCT03823885 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03823885 about?

NCT03823885 is a clinical study titled "ECigs, Inflammation and Oxidative Stress". Randomized controlled trial of acute use of electronic cigarette effect on oxidative stress and inflammation.

What is the current status of trial NCT03823885?

This trial is currently completed. It is a NA study. The enrollment target is 148 participants. The study started on 2019-02-08. Estimated completion is 2023-10-01.

What conditions does trial NCT03823885 study?

This clinical trial studies the following conditions: E-cigarettes, Oxidative Stress, Inflammation.

What interventions are being tested in trial NCT03823885?

The interventions under investigation include: e-cigarette (OTHER), empty (-cigarette sham control) (OTHER).

Who is sponsoring clinical trial NCT03823885?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03823885 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT03823885's enrollment target sits among peer trials

148 702nd of 2000 higher than 1,298 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00739362 · 148 participants · Phase 2

    Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment

  • NCT03161223 · 148 participants · Phase 1

    Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

  • NCT03858231 · 148 participants · Phase 4

    Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery

  • NCT04486352 · 148 participants · Phase 1

    A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03823885, the US trial registry maintained by the National Library of Medicine. NCT03823885 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.